查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2084913

過敏免疫療法市場：2026-2032年全球市場預測（按過敏類型、過敏原類型、免疫療法劑型、技術平台、治療類型、最終用戶和分銷管道分類）

Allergy Immunotherapy Market by Allergy Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Treatment Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，過敏免疫療法市場將成長至 40.7 億美元，複合年成長率為 10.36%。

主要市場統計數據
基準年 2025 20.4億美元
預計年份：2026年 22.4億美元
預測年份 2032 40.7億美元
複合年成長率 (%) 10.36%

過敏免疫療法市場簡介

過敏免疫療法是唯一一種旨在不僅抑制症狀，而且誘導對臨床上重要的過敏原產生免疫耐受性的緩解疾病療法。在實踐中，皮下免疫療法 (SCIT) 和舌下免疫療法 (SLIT) 用於治療過敏性鼻炎、過敏性結膜炎、某些過敏性氣喘、毒素過敏以及某些吸入性過敏原，例如草花粉、豚草、樺樹和屋塵蟎。

過敏免疫療法領域的變革性變化

過敏免疫療法領域正從以萃取物為中心的醫療模式轉向更標準化、以病人為中心且以實證醫學為基礎的治療方案。舌下含服免疫療法（SLIT）片劑的出現拓寬了治療選擇，患者在經過指導性誘導期後即可在家中輕鬆維持治療。另一方面，皮下免疫療法（SCIT）仍然被廣泛應用，因為它允許臨床醫生在受控方案下根據患者的致敏情況調整萃取物組合。

人工智慧（AI）的累積影響

人工智慧（AI）正對過敏免疫療法的研究、商業化和患者管理等各個領域產生累積影響。在藥物發現和開發階段，AI 可以輔助進行過敏原定序、表位定位、製劑最佳化和安全性訊號評估，加速篩選出具有更高療效和耐受性的候選藥物。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

在亞太地區，大規模的人口基數、快速的都市化進程、人們對過敏性鼻炎和氣喘日益成長的認知，以及專科醫療服務的普及，正在推動中國、印度、日本、韓國和澳洲等國過敏免疫療法的發展。由於各國健保體系、過敏原萃取物標準化程度、診斷普及率以及過敏專科醫生密度等方面的差異，市場成熟度存在顯著差異，但隨著患者尋求長期症狀管理方案以及臨床醫生採用更系統的過敏檢測流程，市場需求正在不斷成長。

重點區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協市場，由於都市化進程加快、空氣污染加劇以及中產階級醫療費用支出支出增加，對過敏症診斷和治療的需求日益成長，其重要性也日益凸顯。然而，各成員國在保險報銷、標準化產品的供應以及專科醫生的可及性方面仍然存在差異。海灣合作理事會（GCC）地區預計將迎來高品質過敏症診療服務的擴展，這主要得益於醫療保健投資的增加、私營部門能力的提升、醫療旅遊的活性化以及環境中灰塵、黴菌和室內過敏原的暴露。

對主要過敏免疫療法市場關鍵國家的深入分析。

美國擁有過敏免疫療法領域最大的單一市場機遇，這得益於其完善的過敏專科醫生網路、皮下免疫療法 (SCIT) 的廣泛應用、FDA 監管的口服免疫療法 (SLIT) 片劑，以及支付主導對“醫療需求證明”和“指南導向醫療”的重視。在加拿大，由專科醫生主導的過敏治療和公私合營的醫保報銷機制確保了穩定的市場需求。同時，隨著診斷、都市區專科醫療和醫生培訓的普及，墨西哥和巴西的民營市場潛力也不斷擴大。

為過敏免疫療法領域的領導企業提供的實用建議

產業領導者應優先考慮差異化證據。產品和服務需要基於過敏原、患者表現型、安全性、用藥依從性模式和長期療效進行清晰的臨床定位，而這些定位必須得到隨機試驗、註冊數據和真實世界數據的支持。

調查方法

本執行摘要基於系統性的二手資料研究方法，採用公開可查且檢驗的資訊來源，包括監管指南、專業學會調查方法、同行評審的臨床文獻、產品標籤、流行病學出版物和醫療保健系統文件。參考的資訊來源包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO) 的過敏相關文獻、歐洲過敏與臨床免疫學會 (EAACI)、美國過敏與免疫學會 (AAAI)、美國過敏、氣喘和免疫學會 (ACAAI)、過敏與免疫學協會 (ARIA) 以及各國衛生部門。

結論：過敏免疫療法的前景

過敏免疫療法市場已進入一個更規範化的階段，臨床可靠性、產品標準化、用藥依從性支持以及真實世界的治療效果是決定市場競爭力的關鍵因素。雖然皮下免疫療法（SCIT）仍然是過敏專科醫師診療的基礎療法，但舌下免疫療法（SLIT）正在擴大其針對特定過敏原的便利性和標準化程度。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 過敏免疫療法市場：依過敏類型分類

  • 過敏性氣喘
  • 過敏性鼻炎
  • 異位性皮膚炎
  • 麻疹

第8章 過敏免疫療法市場：依過敏原類型分類

  • 動物皮屑
    • 貓過敏原
    • 狗過敏原
  • 屋塵蟎
  • 食物過敏原
    • 雞蛋過敏原
    • 牛奶過敏原
    • 花生過敏原
    • 堅果過敏原
  • 花粉

第9章 過敏免疫療法市場：依免疫療法劑型分類

  • 經皮吸收貼片
  • 眼藥水
  • 注射藥物
  • 藥片

第10章 過敏免疫療法市場：依技術平台分類

  • 佐劑
  • 基於奈米技術的平台
  • 重組過敏原

第11章 過敏免疫療法市場：依治療類型分類

  • 經皮免疫療法
  • 口服免疫療法
  • 皮下免疫療法
  • 舌下免疫療法

第12章 過敏免疫療法市場：依最終用戶分類

  • 居家照護環境
  • 醫院
  • 研究和學術機構
  • 專科診所

第13章：過敏免疫療法市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 過敏免疫療法市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 過敏免疫療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 過敏免疫療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Adamis Pharmaceuticals Corporation
  • Aimmune Therapeutics Inc.
  • ALK-Abello A/S
  • Allergopharma GmbH & Co. KG
  • Allergy Therapeutics plc
  • Allovate LLC
  • Anergis SA
  • ASIT Biotech SA
  • Biomay AG
  • Camallergy Ltd.
  • Circassia Pharmaceuticals Inc.
  • DBV Technologies SA
  • Desentum Oy
  • HAL Allergy BV
  • HollisterStier Allergy Inc.
  • Inimmune Corporation
  • Inmunotek SL
  • Intrommune Therapeutics, Inc.
  • Jubilant HollisterStier LLC
  • LETI Pharma SL
  • Leti-allergoid
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Prota Therapeutics Pty Ltd
  • Siolta Therapeutics, Inc.
  • Stallergenes Greer International AG
  • Thermo Fisher Scientific Inc.
  • Torii Pharmaceutical Co., Ltd.
  • WOLW Pharma Limited
Product Code: MRR-436901065A53

The Allergy Immunotherapy Market is projected to grow by USD 4.07 billion at a CAGR of 10.36% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.04 billion
Estimated Year [2026] USD 2.24 billion
Forecast Year [2032] USD 4.07 billion
CAGR (%) 10.36%

Allergy Immunotherapy Market Introduction

Allergy immunotherapy is the only disease-modifying treatment class designed to induce immune tolerance to clinically relevant allergens rather than only suppress symptoms. In practice, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are used for allergic rhinitis, allergic conjunctivitis, selected allergic asthma, venom hypersensitivity, and specific inhalant allergens such as grass pollen, ragweed, birch, and house dust mite.

The allergy immunotherapy market is shaped by the persistent global burden of allergic rhinitis and asthma, guideline-backed use in appropriately selected patients, and rising demand for long-term control when antihistamines, intranasal corticosteroids, and allergen-avoidance strategies are insufficient. Regulatory agencies, including the U.S. FDA and European medicines authorities, continue to emphasize standardized allergen extracts, evidence-based labeling, pharmacovigilance, and patient safety, while professional societies such as EAACI, AAAAI, ACAAI, and ARIA reinforce the role of allergen immunotherapy in integrated allergy care.

Commercial momentum is strongest where accurate diagnosis, specialist referral, reimbursement, and adherence support converge. Stakeholders that combine clinically validated products, reliable allergen extract supply, digital adherence tools, and real-world evidence generation are best positioned in the allergy immunotherapy market.

Transformative Shifts in the Allergy Immunotherapy Landscape

The allergy immunotherapy landscape is moving from clinic-administered, extract-centered models toward more standardized, patient-centric, evidence-driven care. SLIT tablets have expanded the treatment conversation by offering convenient, at-home maintenance dosing after supervised initiation, while SCIT remains widely used because clinicians can tailor extract combinations to sensitization profiles under controlled protocols.

Several structural shifts are redefining competition. Climate-related pollen season lengthening, urban air pollution exposure, indoor allergen exposure, and higher awareness of allergic rhinitis and asthma comorbidity are increasing demand for durable interventions. At the same time, regulators and payers are scrutinizing clinical endpoints, product consistency, safety monitoring, and long-term value, pushing manufacturers toward stronger trial design and post-market evidence.

The market is also shifting toward precision allergy management. Component-resolved diagnostics, molecular allergy testing, and better patient phenotyping help differentiate clinically relevant sensitization from cross-reactivity, improving candidate selection and reducing avoidable treatment failure. This supports a more outcome-oriented allergy immunotherapy market with higher emphasis on adherence, persistence, and measurable quality-of-life gains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across allergy immunotherapy research, commercialization, and patient management. In discovery and development, AI can support allergen sequence analysis, epitope mapping, formulation optimization, and safety signal review, accelerating the identification of candidates with improved efficacy and tolerability profiles.

In clinical operations, AI-enabled analytics can help improve trial recruitment by matching sensitization patterns, symptom history, geography, pollen exposure, and comorbid asthma status to protocol requirements. In care delivery, predictive models can flag patients at risk of non-adherence, missed injections, adverse reactions, or symptom escalation, enabling more timely clinician outreach and improved treatment persistence.

The most credible AI impact will come from transparent, validated tools integrated with electronic health records, pharmacy data, diagnostic results, wearable data where available, and environmental exposure datasets such as pollen and air-quality monitoring. Industry leaders should treat AI as an evidence amplifier rather than a substitute for controlled trials, physician judgment, and regulatory-grade pharmacovigilance.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

In Asia-Pacific, allergy immunotherapy development is supported by large populations, rising urbanization, increasing recognition of allergic rhinitis and asthma, and expanding access to specialist care in China, India, Japan, South Korea, and Australia. Market maturity varies widely because reimbursement, allergen extract standardization, diagnostic coverage, and allergy specialist density differ across countries; however, demand is rising as patients seek longer-term symptom control and clinicians adopt more structured allergy testing pathways.

North America remains a highly developed allergy immunotherapy region, led by the United States and Canada, where SCIT is deeply embedded in allergy practice and FDA-approved SLIT tablets provide standardized options for selected allergens. Latin America, including Brazil and Mexico, presents a growing but uneven opportunity as private care access, diagnostic capacity, physician training, and availability of standardized extracts influence uptake across urban and specialty-care settings.

Europe is a mature and clinically influential allergy immunotherapy market supported by strong guideline adoption, national reimbursement structures, pharmacovigilance systems, and well-established regulatory expectations for product quality and evidence. The Middle East, particularly GCC countries, is gaining attention as allergic disease is influenced by dust exposure, indoor allergens, climate conditions, and air quality, while Africa remains an emerging opportunity where access to allergy diagnostics, specialist infrastructure, affordability, and consistent product supply are primary constraints.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly relevant as urban growth, air pollution exposure, and middle-class healthcare spending raise demand for allergy diagnosis and treatment, although reimbursement, standardized product availability, and specialist access remain inconsistent across member countries. The GCC is positioned for premium allergy care expansion because of healthcare investment, private-sector capacity, medical tourism activity, and environmental exposure to dust, molds, and indoor allergens.

The European Union provides one of the most structured environments for allergy immunotherapy, with harmonized regulatory expectations, established pharmacovigilance, and strong clinical society influence across allergic rhinitis, allergic asthma, and venom allergy care. BRICS countries represent high-volume potential, especially China, India, Brazil, and South Africa, but require localized pricing, scalable diagnostics, cold-chain reliability where applicable, and evidence that fits diverse public and private healthcare systems.

G7 markets offer a strong combination of regulatory clarity, payer evaluation, clinical infrastructure, and innovation financing, making them central to product launches, real-world evidence programs, and long-term adherence models. NATO countries overlap substantially with North American and European developed markets, where resilient supply chains, medical preparedness, cross-border quality standards, and established pharmacovigilance support stable access to regulated allergen immunotherapy products.

Key Country Insights Across Major Allergy Immunotherapy Markets

The United States is the largest single commercial opportunity within allergy immunotherapy because of its established allergist network, extensive SCIT use, FDA-regulated SLIT tablets, and payer-driven emphasis on documented medical necessity and guideline-aligned care. Canada shows steady demand through specialist-led allergy care and public-private reimbursement pathways, while Mexico and Brazil offer expanding private-market potential as diagnostic access, urban specialty care, and physician training improve.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from mature allergy practice patterns, guideline awareness, and established pathways for allergic rhinitis, asthma comorbidity assessment, and venom hypersensitivity management. Germany and France are particularly important because of their long-standing clinical adoption of allergen immunotherapy and emphasis on standardized products. Russia has demand potential due to allergic disease burden but faces market-access, regulatory, and supply-chain complexity, while the broader European environment continues to prioritize standardized extracts and evidence-based use.

China and India represent major long-term opportunities due to large allergic disease populations, urban air quality challenges, increasing healthcare spending, and expanding specialty care, though affordability, diagnostic coverage, and physician training remain critical. Japan, South Korea, and Australia are more developed Asia-Pacific markets with stronger regulatory systems, higher diagnostic awareness, and clearer clinical adoption pathways, making them attractive for standardized SLIT and high-quality SCIT portfolios supported by adherence monitoring and post-market evidence.

Actionable Recommendations for Allergy Immunotherapy Leaders

Industry leaders should prioritize differentiated evidence. Products and services need clear clinical positioning by allergen, patient phenotype, safety profile, adherence pattern, and long-term outcome, supported by randomized trials, registry data, and real-world evidence.

Manufacturers should strengthen supply-chain resilience for standardized allergen extracts, invest in physician and patient education, and build digital adherence programs that reduce discontinuation across multi-year treatment courses. Partnerships with diagnostic providers can improve patient selection and help align immunotherapy initiation with clinically relevant sensitization rather than sensitization alone.

Commercial teams should localize market access strategy by reimbursement maturity. In developed markets, value messaging should focus on disease modification, reduced symptom burden, lower medication reliance, and quality-of-life improvement; in emerging markets, success depends on affordability, specialist training, scalable diagnostic pathways, and reliable availability of regulated products.

Research Methodology

This executive summary is based on a structured secondary-research methodology using publicly available and verifiable sources, including regulatory guidance, professional society guidelines, peer-reviewed clinical literature, product labels, epidemiology publications, and health-system documentation. Sources considered include agencies and organizations such as the FDA, EMA, WHO-linked allergy literature, EAACI, AAAAI, ACAAI, ARIA, and national health authorities.

The analysis emphasizes triangulation across clinical evidence, regulatory status, regional healthcare infrastructure, reimbursement context, diagnostic access, and market-access conditions. No unsupported market sizing, market share, or speculative forecasting is included; insights are framed around documented disease burden, approved treatment modalities, observed care pathways, regulatory standards, and validated industry drivers.

Qualitative assessment was applied to compare regions, country groups, and major national markets based on specialist availability, diagnostic capacity, product standardization, patient adherence requirements, payer acceptance, pharmacovigilance systems, and supply-chain reliability.

Conclusion: Outlook for Allergy Immunotherapy

The allergy immunotherapy market is entering a more disciplined phase in which clinical credibility, product standardization, adherence support, and real-world outcomes determine competitive strength. SCIT remains foundational in specialist allergy practice, while SLIT expands convenience and standardization for selected allergens.

Future advancement will depend on precise diagnosis, patient selection, sustained treatment persistence, and evidence that demonstrates durable benefits beyond symptomatic relief. Stakeholders that combine validated immunotherapy portfolios with AI-enabled analytics, regional market access expertise, reliable supply chains, and strong pharmacovigilance will be best positioned to lead the next stage of allergy care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Allergy Immunotherapy Market, by Allergy Type

  • 7.1. Allergic Asthma
  • 7.2. Allergic Rhinitis
  • 7.3. Atopic Dermatitis
  • 7.4. Urticaria

8. Allergy Immunotherapy Market, by Allergen Type

  • 8.1. Animal Dander
    • 8.1.1. Cat Allergens
    • 8.1.2. Dog Allergens
  • 8.2. Dust Mites
  • 8.3. Food Allergens
    • 8.3.1. Egg Allergens
    • 8.3.2. Milk Allergens
    • 8.3.3. Peanut Allergens
    • 8.3.4. Tree Nut Allergens
  • 8.4. Pollen

9. Allergy Immunotherapy Market, by Immunotherapy Delivery Form

  • 9.1. Dermal Patch
  • 9.2. Drops
  • 9.3. Injections
  • 9.4. Tablets

10. Allergy Immunotherapy Market, by Technology Platform

  • 10.1. Adjuvants
  • 10.2. Nanotechnology-Based Platforms
  • 10.3. Recombinant Allergens

11. Allergy Immunotherapy Market, by Treatment Type

  • 11.1. Epicutaneous Immunotherapy
  • 11.2. Oral Immunotherapy
  • 11.3. Subcutaneous Immunotherapy
  • 11.4. Sublingual Immunotherapy

12. Allergy Immunotherapy Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Research & Academic Laboratories
  • 12.4. Specialty Clinics

13. Allergy Immunotherapy Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Allergy Immunotherapy Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Allergy Immunotherapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Allergy Immunotherapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Adamis Pharmaceuticals Corporation
  • 18.2. Aimmune Therapeutics Inc.
  • 18.3. ALK-Abello A/S
  • 18.4. Allergopharma GmbH & Co. KG
  • 18.5. Allergy Therapeutics plc
  • 18.6. Allovate LLC
  • 18.7. Anergis SA
  • 18.8. ASIT Biotech SA
  • 18.9. Biomay AG
  • 18.10. Camallergy Ltd.
  • 18.11. Circassia Pharmaceuticals Inc.
  • 18.12. DBV Technologies SA
  • 18.13. Desentum Oy
  • 18.14. HAL Allergy B.V.
  • 18.15. HollisterStier Allergy Inc.
  • 18.16. Inimmune Corporation
  • 18.17. Inmunotek S.L.
  • 18.18. Intrommune Therapeutics, Inc.
  • 18.19. Jubilant HollisterStier LLC
  • 18.20. LETI Pharma S.L.
  • 18.21. Leti-allergoid
  • 18.22. Merck KGaA
  • 18.23. Mylan N.V.
  • 18.24. Novartis AG
  • 18.25. Prota Therapeutics Pty Ltd
  • 18.26. Siolta Therapeutics, Inc.
  • 18.27. Stallergenes Greer International AG
  • 18.28. Thermo Fisher Scientific Inc.
  • 18.29. Torii Pharmaceutical Co., Ltd.
  • 18.30. WOLW Pharma Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL URTICARIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL URTICARIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL URTICARIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL DANDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL DANDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL DANDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DOG ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOG ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DOG ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DUST MITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DUST MITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DUST MITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FOOD ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FOOD ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FOOD ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EGG ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EGG ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EGG ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MILK ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MILK ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MILK ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POLLEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POLLEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POLLEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DERMAL PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DERMAL PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DERMAL PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DROPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DROPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DROPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADJUVANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADJUVANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 342. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 343. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 348. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 349. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2032 (USD MILLION)
  • TABLE 352. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 353. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2032 (USD MILLION)
  • TABLE 354. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)